Plain-English translation of NCT04650243 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Primary Biliary Cholangitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether patients with primary biliary cholangitis (an autoimmune liver disease) whose condition has improved on treatment can safely take lower doses of . Right now, patients typically take a standard dose for life, but this study wants to see if smaller doses work just as well for people whose disease is under control.
Many patients with this liver condition improve significantly on the standard dose of this medication, but taking it for life can be expensive and burdensome. This trial explores whether people whose disease is stable can take smaller doses, which could reduce cost and side effects while maintaining their health.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either a lower dose or the standard dose of the medication by mouth every day. You will visit the clinic every three months for about 2 years, where your blood will be tested to measure liver function, and your symptoms and quality of life will be checked. The study team will watch carefully to make sure your liver stays healthy on whatever dose you receive.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
China